6533b833fe1ef96bd129ca88
RESEARCH PRODUCT
Combination of eribulin (E) and capecitabine (C) in elderly metastatic breast cancer (MBC): Update of a new option suitable in older elderly.
Antonio RussoDario CovaIgnazio CarrecaGiuseppe BronteAnna Paola CarrecaViviana Bazansubject
OncologyCancer Researchmedicine.medical_specialtyChemotherapyMicrotubule dynamicsMesylatebusiness.industrymedicine.medical_treatmentPharmacologymedicine.diseaseMetastatic breast cancerCapecitabinechemistry.chemical_compoundOncologychemistryInternal medicinemedicinebacteriabusinessmedicine.drugEribulindescription
9540 Background: E mesylate, a nontaxane microtubule dynamics inhibitor is widely prescribed for MBC pts pretreated with at least 1-2 lines of chemotherapy, including anthracyclines and taxanes (A&...
year | journal | country | edition | language |
---|---|---|---|---|
2015-05-20 | Journal of Clinical Oncology |